ABT-888 + Temozolomide
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Non-hematologic Malignancies
Conditions
Non-hematologic Malignancies, Metastatic Melanoma, Breast Cancer, Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer, Hepatocellular Carcinoma
Trial Timeline
Aug 1, 2007 → —
NCT ID
NCT00526617About ABT-888 + Temozolomide
ABT-888 + Temozolomide is a phase 1 stage product being developed by AbbVie for Non-hematologic Malignancies. The current trial status is completed. This product is registered under clinical trial identifier NCT00526617. Target conditions include Non-hematologic Malignancies, Metastatic Melanoma, Breast Cancer.
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01085422 | Phase 1 | Completed |
| NCT00526617 | Phase 1 | Completed |
Competing Products
3 competing products in Non-hematologic Malignancies
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| PTK787/ZK 222584 + paclitaxel | Novartis | Phase 1 | 21 |
| CP-751,871 + Docetaxel | Pfizer | Phase 1 | 29 |
| PF-04605412 | Pfizer | Phase 1 | 21 |